A vs ACAD
Agilent Technologies vs ACADIA Pharmaceuticals Inc. — AI-powered side-by-side comparison
A
Agilent Technologies
70
Buy
VS
ACAD
ACADIA Pharmaceuticals Inc.
71
Buy
| Metric | A | ACAD |
|---|
| AI Score |
70
|
71
|
| Price |
$148.45
|
$29.02
|
| P/E Ratio |
29.77×
|
12.55×
|
| ROE |
19.3%
|
31.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
91.1%
|
| Debt / Equity |
0.47×
|
0.06×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
72.2
|
55.3
|
| Beta |
1.229
|
0.845
|
| Expected Upside |
+0.4%
|
+0.4%
|
AI Committee View
Current Innellis committee reasoning for A versus ACAD.
ACAD leads by 1 points.
ACAD scores 71/100 (Buy) versus A at 70/100 (Buy).
A Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
- Bollinger bandwidth of 16.1% signals elevated volatility — Risk
ACAD Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 26.0% signals elevated volatility — Risk